Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge-Reference-Cited by-同舟云学术

Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge

Published:2018-01-18 Issue:1 Volume:8 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

de Camargo Tarsila Mendes,de Freitas Elisângela Oliveira,Gimenez Alba Marina,Lima Luciana Chagas,de Almeida Caramico Karina,Françoso Kátia Sanches,Bruna-Romero Oscar,Andolina Chiara,Nosten François^ORCID,Rénia Laurent,Ertl Hildegund C. J.,Nussenzweig Ruth S.,Nussenzweig Victor,Rodrigues Mauricio M.,Reyes-Sandoval Arturo^ORCID,Soares Irene S.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-19063-6.pdf

Reference47 articles.

1. WHO. World Malaria Report 2015. WHO Library ISBN 978 92 4 156515 8 (2016).

2. Rahimi, B. A. et al. Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900. Malar J 13, 481 (2014).

3. Ouattara, A. & Laurens, M. B. Vaccines against malaria. Clin Infect Dis 60, 930–936 (2015).

4. Garcon, N., Heppner, D. G. & Cohen, J. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines 2, 231–238 (2003).

5. Rts, S. C. T. P. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 11, e1001685 (2014).

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Poly I:C elicits broader and stronger humoral and cellular responses to a Plasmodium vivax circumsporozoite protein malaria vaccine than Alhydrogel in mice;Frontiers in Immunology;2024-04-08

2. Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol®) as adjuvant;Vaccine;2024-04

3. Circumsporozoite Protein from Plasmodium vivax and Its Relationship to Human Malaria;New Advances in Neglected Tropical Diseases;2023-02-22

4. Plasmodium vivax vaccine: What is the best way to go?;Frontiers in Immunology;2023-01-16

5. Heterologous mRNA-protein vaccination with Tc24 induces a robust cellular immune response against Trypanosoma cruzi, characterized by an increased level of polyfunctional CD8+ T-cells;Current Research in Immunology;2023